Review
Accepted on 30 May 2023
Molecular determinants of TRPM8 function: key clues for a cool modulation.
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1213337
Type at least 3 characters
467 articles
Articles
Original Research
Published on 30 May 2023
Effects of lumacaftor—ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2–11 years
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1188051
- 295 views
Original Research
Accepted on 25 May 2023
Proliferative activity of antigen-specific CD154+ T cells against bacterial and fungal respiratory pathogens in Cystic Fibrosis decreases after initiation of highly effective CFTR modulator therapy.
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1180826
Original Research
Accepted on 22 May 2023
SPIROMETRIC AND ANTHROPOMETRIC IMPROVEMENTS IN RESPONSE TO ELEXACAFTOR/TEZACAFTOR/IVACAFTOR DEPEND ON AGE AND LUNG DISEASE SEVERITY
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1171544
- 105 views
Original Research
Published on 22 May 2023
SERCA inhibition improves lifespan and healthspan in a chemical model of Parkinson disease in Caenorhabditis elegans
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1182428
- 416 views
Original Research
Published on 19 May 2023
Thoracic epidural analgesia prolongs postoperative QT interval on electrocardiogram in major non-cardiac surgery: a randomized comparison and a prospective cohort analysis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.936242
- 626 views
Original Research
Published on 09 May 2023
Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1176815
- 767 views
Brief Research Report
Published on 27 Apr 2023
Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1156621
- 737 views
Original Research
Published on 25 Apr 2023
Immunohistochemical, pharmacovigilance, and omics analyses reveal the involvement of ATP-sensitive K+ channel subunits in cancers: role in drug–disease interactions
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1115543
- 654 views
Original Research
Published on 25 Apr 2023
Immunocytoprotection after reperfusion with Kv1.3 inhibitors has an extended treatment window for ischemic stroke
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1190476
- 495 views
Original Research
Published on 21 Apr 2023
Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1179208
- 623 views
Original Research
Published on 13 Apr 2023
Unravelling the allosteric binding mode of αD-VxXXB at nicotinic acetylcholine receptors
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1170514
- 838 views
Editorial
Published on 12 Apr 2023
Editorial: Emerging talents in pharmacology of ion channels and channelopathies 2022
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1191328
- 347 views
Review
Published on 31 Mar 2023
Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1151244
- 1,979 views
Mini Review
Published on 27 Mar 2023
Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1163391
- 1,479 views
Original Research
Published on 27 Mar 2023
Differential effects of ELX/TEZ/IVA on organ-specific CFTR function in two patients with the rare CFTR splice mutations c.273+1G>A and c.165-2A>G
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1153656
- 529 views
- 1 citations